Wythenshawe Hospital Transplant Fund Financial statements

for

the year ended 31 March 2017

Company Registration Number 2977135 Charity Number 1049067

BEEVER AND STRUTHERS

Chartered Accountants St. George's House 215 - 219 Chester Road Manchester M15 4JE

Financial statements

Year ended 31 March 2017

Contents	Pages
Members of the board and professional advisers	1
Chairman's statement	2
Trustees' annual report	3 to 4
Strategic report	5
Responsibilities of the Trustees	6
Independent examiner's report to the members	7
Statement of financial activities (incorporating the income and expenditure account)	8
Balance sheet	9
Notes to the financial statements	10 to 15

Members of the board and professional advisers

Registered charity name

Wythenshawe Hospital Transplant Fund

Charity number

1049067

Company registration number

2977135

Principal and registered office

The Transplant Fund Office

Transplant Centre Wythenshawe Hospital

Manchester M23 9LT

Trustees

Dr M Al-aloul

B Clare (appointed 4 July 2017)

R G Dyson (Chairman)

N Eadie PJ Nichols W Noble B E Quick M J Seal

R Venkateswaran (appointed 4 July 2017)

N Yonan (retired 4 July 2017)

Secretary

L C Ellis

Independent examiner

Maria M Hallows BA FCA

St. George's House 215 - 219 Chester Road

Manchester M15 4JE

Bankers

HSBC Bank plc

11 Stamford New Road

Altrincham WA14 1BW

W H Ireland Ltd 11 St James's Square

Manchester M2 6WH

Solicitors

Addleshaw Goddard

One St Peter's Square

Manchester M2 3DE

Chairman's statement

Year ended 31 March 2017

Our income from fundraising events raised £47,000 this year, reflecting the significant efforts of those who have organised and run fundraising events on behalf of the charity. Such events included Sponsored Slimming, Runs, Walks, Balls, Birthday Parties, Supermarket Collections and Cake Sales to name but a few The 200 Club, which now has 173 members, also contributed over £2,500 in its first year

We have recently upgraded our website and both changed the format and increased the size of our biannual newsletter. Both these change have resulted in better awareness of our activities generally.

We continue to be greatly indebted to the generosity of many friends and supporters who do much for the charity.

During the year the charity has incurred expenditure on a number of major projects, including:

- £60,000 to acquire a replacement bronchoscopy camera. This allows the unit to carry lung biopsies without the need to send patients to other departments in the Hospital.
- £44,000 to fund continued research at the Transplant Laboratory into the impact of changing to a Mediterranean diet and to fund three research students.
- £15,000 to acquire a specialist combilizer which enables patients to be transferred more easily to a sitting position, thereby helping facilitating patient recovery
- £12,000 mobile ultrasound equipment for use on the ward.

We have also continued to contribute to the costs of recipients who participate in the Transplant Games (both National and European) and to provide support to other recipients to meet any emergency financial crisis that they may suffer due to their condition pre or post Transplant.

It is pleasing to report that three of the perfusion kits purchased last year for use in a recently developed innovative organ care system have been used to perform DBD (Donation after Brain Death) transplants and three of the kits have been used to perform DCD (Donation after Circulatory Death) transplants. All six recipients are recovering well. These kits should enable the Transplant Centre to carry out 10%-20% more heart transplants per annum and should help in bringing down the waiting list, particularly for non urgent cases.

Our firm commitments at the year end of £204,000 include the cost of purchasing an additional six perfusion kits and development of a detailed protocol to enable patients to follow healthy eating and lifestyle advice following transplantation.

The charity's office continues to be well managed by Lynda Ellis, who has demonstrated very effectively her considerable experience in fundraising and volunteer co-ordination, and we are very grateful to her for all her work with patients and supporters.

My fellow trustees willingly give their time for the charity's benefit and I thank them for their continued efforts. Our efforts will continue to ensure that the Transplant Centre is equipped with the latest technology to ensure that Wythenshawe remains at the forefront of excellence for the treatment of heart and lung transplantation.

Richard Dyson Chairman 6 September 2017

Trustees' annual report

Year ended 31 March 2017

The Trustees, who are also directors for the purposes of company law, have pleasure in presenting their report and the financial statements of the charity for the year ended 31 March 2017.

The Trustees

The Trustees who served the company during the period were as follows:

Dr M Al-aloul

B Clare (appointed 4 July 2017)

R G Dyson (chairman)

N Eadie

P J Nichols

W Noble

Mrs B E Quick

M J Seal

R Venkateswaran (appointed 4 July 2017)

N Yonan (retired 4 July 2017)

Structure, governance and management

Wythenshawe Hospital Transplant Fund is a company limited by guarantee but not having a share capital and is registered as a charity under the Charities Act 1993.

Under paragraph 6 of the company's Memorandum, every Trustee undertakes to contribute to the assets of the company in the event of it being wound up while he or she is a member, or within one year after they cease to be a member and of the costs, charges and expenses of winding up, and for the adjustment of the rights of contributors among themselves, such amount as may be required, not exceeding £1 per member.

Organisation

The charity is controlled by a Board of Trustees which elects a Chairman and Company Secretary. The operations of the charity are set by the Chairman to whom the full time administrator of the charity reports. Additional assistance is provided by unpaid supporters and the Trustees.

All significant decisions regarding the charity are taken or confirmed at quarterly Trustees' meetings.

Appointment of Trustees

No person may be appointed as a Trustee unless approved by all the Trustees. At every general meeting one third of the Trustees retire by rotation being decided by the length of time in office. Subject to the above, University Hospital South Manchester NHS Foundation Trust may appoint a Trustee. Trustees must be aged 18 years or above and not disqualified by reason of Article 10.1 of the charity's Articles of Association.

None of the Trustees have any interest in the charity. Trustees are appointed under the provision of Articles 31 to 33 of the charity's Articles of Association.

Trustee induction and training

All new Trustees receive a formal briefing from the Chairman of their duties and responsibilities and receive various booklets from the Charity Commission and Companies House. They are also encouraged to keep themselves abreast of current and proposed developments in charity regulation through access to the Charity Commission website and other relevant sources of information.

Related parties

The charity is stand-alone organisation with no subsidiaries.

Trustees' annual report (continued)

Year ended 31 March 2017

Objectives and activities for the public benefit

In setting our objectives and planning our activities, the Trustees have given careful consideration to the Charity Commission's general guidance on public benefit.

As determined by the charity's Memorandum and Articles of Association, the principal activity of the charity is to support the programme of heart and lung transplantation at Wythenshawe Hospital, Manchester, serving the North West of England. Whilst the NHS provides substantial funds for the transplant centre there is always a demand for state of the art equipment or money to support pioneering treatments and research which the NHS is unwilling to fund. The charity plays a vital role by providing funds to accelerate the adoption of new procedures and by funding research which advances the technology surrounding transplantation, thus enabling the Wythenshawe Transplant Centre to remain at the forefront of excellence for the treatment of cardiac and lung disease.

The charity is in regular contact with Wythenshawe Hospital and receives funding requests from the hospital. The Trustees determine whether to meet these requests for funding. The charity does not enter into contractual relationships with suppliers of equipment and services. It only provides the agreed funding.

Investment policy and investment returns

The Trustees are empowered to invest and deal with the monies of the charity not immediately required in such a manner as the charity may from time to time determine subject to such conditions and consents imposed or required by law. Surplus funds are placed on deposit either with the charity's bankers or with W H Ireland Ltd or invested in UK Government Stocks, corporate bond funds and unit trusts. Investment returns are governed by the prevailing interest rates and dividend payments.

Small company provisions

This report has been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

Signed on behalf of the Trustees

L C Ellis

tu

Company Secretary 6 September 2017

Strategic report

Year ended 31 March 2017

Achievements and performance

Voluntary donations, legacies and other trading activities raised a total of £95,182 (2016: 131,307), investment income on our investments and cash deposits raised £27,747 (2016: £20,889) and realised gains on our investments generated a further £101,651 (2016: losses £19,232). This allowed the Trustees to continue the charity's support for most of the requests submitted to the charity. During the year the charity has donated £164,859 (2016: £342,556) to fund the purchase of a number of items of equipment for use in the Wythenshawe Transplant Centre, for continuing research, primarily into the impact of changing to a Mediterranean diet, and to contribute to the costs of recipients who participate in the Transplant Games. The total outstanding committed expenditure on these and other projects at the end of the year was £204,000 (2016: £83,000).

The Trustees' policy is to approve all major grants prior to commitment of funds. Minor funding of up to £5,000 may be approved by the Chairman.

Financial review

The results for the year and their impact on the charity's funds are set out in detail in the statement of financial activities on page 8. Total net income for the year was £10,531 (2016: net expenditure £261,959) and the year end net assets amounted to £1,501,862 (2016: £1,491,331), including £1,506,385 (2016: £1,495,586) in cash at the bank or invested in UK Government Stocks, corporate bond funds and Open Ended Investment Companies.

Risk management

The Trustees continue to review the charity's activities to identify the major risks to which it is exposed and the systems established to mitigate risks are periodically reviewed to ensure that they are operating effectively and still meet the needs of the charity. The last such review took place on 4 July 2017.

The principal risks and uncertainties identified through this review were the volatility of investments held by the charity and the continued ability to raise voluntary income. The steps taken by the Trustees to mitigate these risks as far as practicable are to maintain a diversified portfolio of investments and to monitor both investment performance and the level of voluntary income received at each Board meeting.

Plans for future periods

It is the intention of the Trustees to continue to support funding raising activities to raise funds to accelerate the adoption of new procedures and to fund research which advances the technology surrounding transplantation.

Reserves policy

The charity's reserves are represented by its investments and cash balances. The Trustees have reviewed the charity's requirements for unrestricted reserves in the light of the main risks to the organisation. In the opinion of the Trustees, sufficient unrestricted reserves are required to meet one year's operating costs in the event of a significant drop in incoming resources and £50,000 is considered to be adequate for this purpose. The balance of the unrestricted reserves is available to be used to fund projects in accordance with the charity's objects.

Signed on behalf of the Trustees

L C Ellis

Company Secretary 6 September 2017

ten

Responsibilities of the Trustees

Year ended 31 March 2017

The Trustees (who are also the directors of Wythenshawe Hospital Transplant Fund for the purposes of company law) are responsible for preparing the Trustees' annual report, the Chairman's statement and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Statement of Recommended Practice: Accounting and Reporting by Charities;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation,

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. The Trustees are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Independent Examiner's Report to the Trustees of Wythenshawe Hospital Transplant Fund

I report on the accounts of the Company for the year ended 31 March 2017 which are set out on pages 8 to 15.

Respective responsibilities of the Trustees and the examiner

The Trustees who are also the directors of the Company for the purposes of company law are responsible for the preparation of the accounts. The Trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the 2011 Act) and that an independent examination is needed.

Having satisfied myself that the charity is not subject to an audit under company law and is eligible for independent examination, it is my responsibility to:

- examine the accounts under section 145 of the 2011 Act;
- to follow the procedures laid down in the General Directions given by the Charity Commission (under section 145(5)(b) of the 2011 Act; and
- · to state whether particular matters have come to my attention.

Basis of independent examiner's report

My examination was carried out in accordance with the General Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the Charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts and seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and no opinion is given as to whether the accounts present a "true and fair view" and the report is limited to those matters set out in the statement below.

Independent examiner's statement

In connection with my examination, no matter has come to my attention:-

- (1) which gives me reasonable cause to believe that in any material respect the requirements
 - to keep accounting records in accordance with section 386 of the Companies Act 2006; and
 - to prepare accounts which accord with the accounting records and comply with the
 accounting requirements of section 396 of the Companies Act 2006 and with the
 methods and principles of the Statement of Recommended Practice: Accounting and
 Reporting by Charities.

have not been met; or

(2) to which, in my opinion attention should be drawn in order to enable a proper understanding of the accounts to be reached.

Maria Hallois

Name: Maria M Hallows

Relevant professional qualification or body: BA, FCA

Address: St George's House, 215/219 Chester Road, Manchester M15 4JE

Date: 20chober 2017

Statement of financial activities (incorporating the Income and expenditure account)

Year ended 31 March 2017

	Note	Unrestricted funds £	Restricted funds £	Total funds 2017 £	Total funds 2016 £
Income and endowments					
Donations and legacies	2	36,068	6,814	42,882	69,106
Other trading activities	3	52,300	-	52,300	62,201
Investment income	4	27,747		27,747	20,889
Total income and endowme	ents	116,115	_6,814	122,929	152,196
Expenditure					
Raising funds	5	8,717	-	8,717	12,679
Expenditure on charitable					
activities	6	166,929	<u>38,403</u>	205,332	382,244
Total expenditure		175,646	38,403	214,049	394,923
Gains/(losses) on investments	7	101,651		101,651	(19,232)
Net (expenditure) income					
and net movement in funds for the year	8	42,120	(31,589)	10,531	(261,959)
Reconciliation of funds					
Total funds brought forward		1,448,053	43,278	1,491,331	1,753,290
Total funds carried forwar	ď	1,490,173	11,689	1,501,862	1,491,331

All of the above amounts relate to continuing activities.

Balance sheet

31 March 2017

	2017		7	2016		
	Note	£	£	£	£	
Current assets						
Stocks	10	200		200		
Debtors	11	7,375		8,119		
Investments	12	812,713		777,880		
Cash at bank		693,672		717,706		
Total current assets Creditors: amounts falling due		1,513,960		1,503,905		
within one year	13	(12,098)		(12,574)		
Net current assets			1,501,862		1,491,331	
Total assets less current liabilities			1,501,862		1,491,331	
Net assets			1,501,862		1,491,331	
Funds						
Restricted income funds	15		11,689		43,278	
Unrestricted income funds	16		1,490,173		1,448,053	
Total funds			1,501,862		1,491,331	

The Directors are satisfied that the Company is entitled to exemption from the provisions of the Companies Act 2006 (the Act) relating to the audit of the financial statements for the period by virtue of section 477, and that no member or members have requested an audit pursuant to section 476 of the Act.

The Directors acknowledge their responsibilities for:

- ensuring that the Company keeps adequate accounting records which comply with section 386 of the Act, and
- (ii) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial period and of its profit or loss for the financial period in accordance with the requirements of section 393, and which otherwise comply with the requirements of the Act relating to financial statements, so far as applicable to the company.

These financial statements have been prepared in accordance with the special provisions for small companies under part 15 of the Companies Act 2006

These financial statements were approved by the Trustees on 6 September 2017 and are signed on their behalf by:

Richard Dyson

Company registration number: 2977135

dem Dysa.

The notes on pages 10 to 15 form part of these financial statements.

Notes to the financial statements

Year ended 31 March 2017

1. Accounting policies

Basis of accounting

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of certain current assets, and in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006. The date of transition to FRS102 was 1 April 2015.

General information

The charity is a private company limited by guarantee, incorporated in England and Wales (company number: 2977135 and charity number 1049067). The charity's registered office is: The Transplant Fund Office, Transplant Centre, Wythenshawe Hospital, Manchester M23 9LT.

Going concern

The Trustees have, at the time of approving the financial statements, a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus, the Trustees continue to adopt the going concern basis of accounting in preparation of the financial statements.

Public benefit

The company, incorporated on 10 October 1994, is a public benefit entity as defined by FRS 102.

Reconciliation with previous Generally Accepted Accounting Practice

In preparing the financial statements, the Trustees have considered whether, in applying the accounting policies required by FRS102 and the Charities SORP (FRS 102), a reconciliation of opening balances and net income for the year with net income under previous Generally Accepted Accounting Practice (GAAP) needs to be provided. No transitional adjustments were required in opening balances or net income for the year and a reconciliation is not therefore required.

Critical accounting judgements and key sources of estimation uncertainty

The preparation of the financial statements in conformity with FRS 102 requires the use of certain critical accounting estimates. It can also require the Trustees to exercise their judgement in the process of applying the charity's accounting policies. The charity is not considered to have any critical accounting estimates or judgements at this time.

Income

Voluntary income, including donations, gifts and legacies, is recognised as receivable when the charity has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that the income will be received and the amount can be measured reliably. Interest on deposits is recognised on an accruals basis.

Notes to the financial statements (continued)

Year ended 31 March 2017

Expenditure

All expenditure is recognised on an accruals basis as a liability is incurred. Expenditure includes any VAT which cannot be recovered and is reported as part of the expenditure to which it relates. Charitable activities include all costs incurred by the charity in the delivery of its activities and services for its beneficiaries. Such costs include both the costs that can be allocated directly to such activities and those costs necessary to support them.

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Investments

Investments, which include Open Ended Investment Companies authorised in the UK and corporate bond funds, are stated at the closing prices at the balance sheet date. The Statement of Financial Activities includes the net gains and losses arising on revaluation and disposals throughout the year.

Financial instruments

Basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable are accounted for on the following basis:

Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits with financial institutions and other short-term highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash with insignificant risk of change in value.

Debtors and creditors

Debtors are measured at transaction price, less any provision for impairment, and creditors are measured at transaction price.

Fund accounting

Unrestricted funds are funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity. Restricted funds are funds that are to be used in accordance with specific restrictions imposed by donors which have been raised by the charity for a particular purpose. The aim and use of each restricted fund is set out in note 15 to the financial statements.

Notes to the financial statements (continued)

Year ended 31 March 2017

2. D	onations	and	legacies
------	----------	-----	----------

2.	Donations and legacies				
		Unrestricted funds	Restricted funds	Total funds 2017 £	Total funds 2016 £
	Donations Donations	20,773	6,814	27,587	36,752
	Legacies Legacies	552	-	552	17,608
	Gifts In memoriam Sponsorship	14,743	-	14,743	14,746
	Support groups				
		36,068	6,814	42,882	69,106
3.	Other trading activities				
	Fundraising events Charitable trading	Unrestricted funds £ 47,300 _ 5,000	Restricted funds £	Total funds 2017 £ 47,300 5,000	Total funds 2016 £ 57,593 4,608
	Cumuma s	52,300		52,300	<u>62,201</u>
4.	Income from investments				
			Unrestricted funds	Total funds 2017 £	Total funds 2016 £
	Bank interest receivable Interest from Government stocks Income from Open Ended Investr	ment Companies	551 2,049 <u>25,147</u>	551 2,049 <u>25,147</u>	1,342 2,736 16,811

Expenditure on raising funds

Cost of goods sold and other costs Investment management fees	Unrestricted funds £ 3,050 _ 5,667	Total funds 2017 £ 3,050 5,667	Total funds 2016 £ 7,881 4,798
	<u>8,717</u>	<u>8,717</u>	12,679

27,747

20,889

27,747

Notes to the financial statements (continued)

Year ended 31 March 2017

6. Expenditure on charitable activities

	Medical supplies/equipment Laboratory/research Refurbishment of bungalows Other charitable donations Office salaries Administration and other costs	8 1 2 2 1	ricted funds £ 81,793 17,512 - 27,151 25,118 15,355	Restricted funds £ 10,716 26,630 1,057 38,403	92. 44. 1. 27. 25.	017 £ ,509 ,142 ,057 ,151 ,118		tal funds 2016 £ 181,243 70,312 80,289 10,712 24,762 14,926 382,244
7.	Gains (losses) on investments							
	Realised gains(losses) Unrealised gains (losses)			2017 £ 16,701 84,950 				2016 £ 5,679 (24,911) (19,232)
8.	Net (expenditure) income							
	This is stated after charging: Depreciation Independent examiner's fee			2017 £ 2,340				2016 £ 464 2,340
9.	Staff costs and emoluments							
	Total staff costs were as follows:			2017 £				2016 £
	Wages and salaries Social security costs			$ \begin{array}{r} 24,792 \\ \underline{326} \\ 25,118 \end{array} $			-	24,500 262 24,762
	Particulars of employees: The average number of employees equivalents, was as follows:	during	the year,		on the	basis	of	
				2017 No				2016 No
	Number of administrative staff			1				1

No employee received remuneration of more than £60,000 during the year (2016 - Nil).

The Trustees did not receive any remuneration or re-imbursement of expenses (2016 - Nil).

Notes to the financial statements (continued)

Year ended 31 March 2017

N Yonan, a trustee, has deposited funds with the charity. The balance due at the year-end was £4,365 (2016: £5,629) and no interest is paid on this balance. A creditor for this amount is included in other creditors and accruals (note 13).

10.	Stocks	2017	2016
		£	£
	Stock	<u>200</u>	200
11.	Debtors		2016
		2017	2016
		£	£
	Sundry debts receivable	6,862	6,890
	Prepayments	179	179
	Interest receivable	334	1,050
		<u>_7,375</u>	8,119
12.	Investments		2016
		2017	2016
		£	£
	At 1 April 2016	777,880	664,525
	Investment additions	260,314	180,285
	Investment disposals	(327,132)	(47,698)
	Realised investment gains (losses)	16,701	5,679
	Unrealised investment gains (losses)	84,950	(24,911)
	Officialised investment game (1999)		
	At 31 March 2017	812,713	<u>777,880</u>
	Listed investments comprise:		
	Listed investments comprise:	2017	2016
		£	£
		82,898	150,100
	UK Government Stocks		541,049
	Open Ended Investment Companies	669,149	86,731
	Corporate bond funds	60,666	_00,/31
		812,713	777,880

The historic cost of the UK Government Stocks is £75,632 (2016: £150,020), the historic cost of the Open Ended Investment Companies is £579,239 (2016: £527,806) and the historic cost of the corporate bond funds is £60,234 (2016: £90,471).

13. Creditors: amounts falling due within one year

10 04-1-

	2017	2016
	£	£
PAYE and social security	2,671	1,446
Other creditors and accruals	9,427	11,128
	<u>12,098</u>	12,574

Notes to the financial statements (continued)

Year ended 31 March 2017

14. Financial instruments

	2017 £	2016 £
Financial assets measured at fair value through the SOFA Financial assets measured at amortised cost	812,713	$\frac{777,880}{7,940}$ $\frac{7,940}{785,820}$
Financial liabilities measured at amortised cost	(8,963)	(11,060)

- (a) Financial assets measured at fair value include assets held as investments.
- (b) Financial assets measured at amortised cost include trade and other debtors.
- (c) Financial liabilities measured at amortised cost include trade and other creditors.

15. Restricted income funds

	Balance at 1 Apr 2016	Income	Expenditure	Balance at 31 Mar 2017
	£	£	£	£
Equipment - lungs	9,630	-	(9,630)	-
Equipment – other	7,601	6,231	(2,143)	11,689
Research – lungs	17,023	235	(17,258)	-
Research - laboratory	9,024	348	(9,372)	
	43,278	6,814	(38,403)	11,689

The restricted income funds comprise amounts given by donors who indicate that their donations are to be spent on specific items to be used, or projects to be carried out, at Wythenshawe Hospital to further the objects of the charity.

16. Unrestricted income funds

	Balance at			Gains on	Balance at	
	1 Apr 2016	Income	Expenditure	investments	31 Mar 2017	
	£	£	£	£	£	
General funds	1,448,053	116,115	(175,646)	101,651	1,490,173	

17. Analysis of net assets between funds

	Net current		
	Investments	assets	Total
Restricted income funds Unrestricted income funds	<u>-</u> 812,713	11,689 <u>677,460</u>	11,689 1,490,173
Total funds	812,713	689,149	1,501,862